Segment Data

6 Months Ended

Mar. 31, 2021

Segment Reporting [Abstract]

Segment Data

Segment Data

The Company's organizational structure is based upon three worldwide business segments: BD Medical (“Medical”), BD Life Sciences (“Life Sciences”) and BD Interventional ("Interventional"). The Company's segments are strategic businesses that are managed separately because each one develops, manufactures and markets distinct products and services. Segment disclosures are on a performance basis consistent with internal management reporting. The Company evaluates performance of its business segments and allocates resources to them primarily based upon segment operating income, which represents revenues reduced by product costs and operating expenses.

Revenues by segment, organizational unit and geographical areas for the three and six-month periods are detailed below. The Company has no material intersegment revenues.

	Three Months Ended March 31,
(Millions of dollars)	2021						2020
	United States		International		Total		United States		International		Total
Medical
Medication Delivery Solutions	$	531	$	468	$	999	$	518	$	386	$	904
Medication Management Solutions	440		126		566		449		119		568
Diabetes Care	148		135		284		142		137		278
Pharmaceutical Systems	100		361		462		91		309		400
Total segment revenues	$	1,220	$	1,091	$	2,311	$	1,200	$	951	$	2,151
Life Sciences
Integrated Diagnostic Solutions	$	454	$	807	$	1,261	$	413	$	420	$	833
Biosciences	121		204		325		108		172		280
Total segment revenues	$	576	$	1,010	$	1,586	$	522	$	591	$	1,113
Interventional
Surgery	$	227	$	65	$	292	$	249	$	63	$	312
Peripheral Intervention	222		198		420		242		157		399
Urology and Critical Care	217		82		298		202		76		279
Total segment revenues	$	666	$	345	$	1,011	$	693	$	297	$	990
Total Company revenues	$	2,462	$	2,446	$	4,907	$	2,415	$	1,839	$	4,253

	Six Months Ended March 31,
(Millions of dollars)	2021						2020
	United States		International		Total		United States		International		Total
Medical
Medication Delivery Solutions	$	1,099	$	908	$	2,006	$	1,038	$	814	$	1,852
Medication Management Solutions	917		278		1,196		912		231		1,143
Diabetes Care	298		271		569		281		266		547
Pharmaceutical Systems	180		621		801		174		525		699
Total segment revenues	$	2,494	$	2,078	$	4,572	$	2,404	$	1,836	$	4,241
Life Sciences
Integrated Diagnostic Solutions	$	1,469	$	1,459	$	2,928	$	799	$	834	$	1,633
Biosciences	241		396		637		260		342		603
Total segment revenues	$	1,710	$	1,855	$	3,565	$	1,060	$	1,176	$	2,236
Interventional
Surgery	$	489	$	135	$	624	$	505	$	133	$	638
Peripheral Intervention	454		392		846		467		327		794
Urology and Critical Care	445		171		616		409		161		570
Total segment revenues	$	1,388	$	698	$	2,086	$	1,381	$	621	$	2,002
Total Company revenues	$	5,592	$	4,631	$	10,223	$	4,845	$	3,634	$	8,479

Segment income for the three and six-month periods was as follows:

	Three Months Ended March 31,				Six Months Ended March 31,
(Millions of dollars)	2021		2020		2021		2020
Income Before Income Taxes
Medical (a)	$	634	$	443	$	1,300	$	1,007
Life Sciences (b)	548		285		1,521		646
Interventional	209		213		511		455
Total Segment Operating Income	1,392		941		3,331		2,109
Acquisitions and other restructurings	(52)		(75)		(102)		(161)
Other operating expense (c)	(296)		—		(296)		—
Net interest expense	(122)		(132)		(238)		(266)
Other unallocated items (d)	(618)		(534)		(1,233)		(1,087)
Total Income Before Income Taxes	$	305	$	200	$	1,462	$	594

(a)The amounts include a charge of $37 million for the three and six months ended March 31, 2021, and charges of $199 million and $258 million, for the three and six months ended March 31, 2020, respectively, recorded to Cost of products sold, related to the estimate of costs associated with remediation efforts for AlarisTM infusion pumps in the Medication Management Solutions unit.

(b)The amounts for the three and six-month periods ended March 31, 2020 included a charge of $39 million recorded to Cost of products sold to write down the carrying value of certain intangible assets in the Biosciences unit.

(c)The amounts for the three and six-month periods in 2021 consisted of pre-tax charges related to certain product liability matters, which is further discussed in Note 5.

(d)Primarily comprised of foreign exchange, certain general and administrative expenses and share-based compensation expense.